110 likes | 261 Views
Three key messages on tuberculosis control. World Tuberculosis Day 2010. ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March 2010. Message 1 The treatment success rate in the EU/EEA is too low to meet global targets.
E N D
Three key messages on tuberculosis control World Tuberculosis Day 2010 ECDC TB TeamEuropean Centre for Disease Prevention and Control Stockholm, 24 March 2010
Message 1 The treatment success rate in the EU/EEA is too low to meet global targets
1a. The treatment success rate in the EU/EEA is too low to meet global targets • Reported treatment success rates in the EU/EEA are far below the 85% target set by the WHO World Health Assembly. Only three EU/EEA countries recorded a treatment success rate over 85% or more for new laboratory-confirmed pulmonary TB cases. Figure 1a: Treatment success rate among new laboratory-confirmed pulmonary TB cases, 2007 85% target set by the Stop TB Partnership. Only Iceland, Portugal and Slovakia meet the 85% target. * Treatment success rate among not previously diagnosed cases. Source: ECDC
1b. The treatment success rate in the EU/EEA is too low to meet global targets Figure 1b: Percentage success rate among laboratory-confirmed new pulmonary TB cases, EU/EEA, 2007 < 60% 60 to 70% 71 to 84% ≥ 85% Not included or not reporting • Source: ECDC
1c. The treatment success rate in the EU/EEA is too low to meet global targets • Treatment success among previously untreated laboratory-confirmed pulmonary TB remains low in the EU/EEA and is below the 85% target. No changes in the trend were seen in the last five years. • Figure 1c: EU/EEA treatment outcome among laboratory-confirmed pulmonary cases 2003–2007 Transferred or unknown Still on treatment 100 90 80 70 60 50 40 30 20 10 0 Defaulted Failed Died Success • * Excluded: Austria, Bulgaria, Cyprus, Finland, France, Greece, Italy, Liechtenstein and Spain
Message 2 Multidrug-resistant tuberculosis (MDR TB) remains a problem in the EU/EEA
Figure 2a: Proportion of notified TB cases with primary multidrug resistance, EU/EEA, 2008 2a. MDR TB* remains a problem in the EU/EEA < 1% 1 to 1.9% 2 to 5.9% > 6-10% > 10% Not included or not reporting * Multidrug-resistant tuberculosis (MDR TB) is defined as TB that is resistant at least to isoniazid (INH) and rifampicin (RMP), the two most powerful first-line anti-TB drugs.
90 78% 80 70 60 50 40 31% 30 17% 17% 17% 20 13% 7% 10 6% 5% 5% 3% 2% 0 MDR MDR MDR MDR MDR MDR Success Died Failed Defaulted Still on treatment Transferred or unknown 2b. MDR TB remains a problem in the EU/EEA • Treatment success rate among MDR TB cases is extremely low (31%). • Figure 2b: Treatment outcome of all* MDR TB cases, compared to all non-MDR cases, EU/EEA, 2006** Non-MDR Non-MDR Non-MDR Non-MDR Non-MDR Non-MDR * Pulmonary and extra-pulmonary ** Both groups are 2006 treatment cohorts
Message 3 The decline in tuberculosis has levelled off in the EU/EEA
3a. The decline in tuberculosis has levelled off in the EU/EEA • The decrease in TB notification rates has stagnated in the EU/EEA. • The decline seen in countries with high and intermediate incidence rates contributes substantially to the average EU/EEA decline. • Figure 3a:TB notification rates by incidence grouping, 1995–2008 and 2002–2008 >20/100 000 Notification rate (per 100 000 population) EU/EEA <20/100 000 • Source: ECDC
3b. The decline in tuberculosis has levelled off in the EU/EEA • Figure 3b:TB notification rates, 1995–2008, EU/EEA 2000 2002 2004 2006 2008 25 20 15 10 5 0 2001 2003 2005 2007 1995 1997 1999 1996 1998 Notification rate (per 100 000 population)